.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently published a systematic review highlighting the incidence of Rituximab-induced hypogammaglobulinemia in pediatric nephrotic syndrome. Rituximab effectively treats complicated cases, such as steroid-dependent or frequently relapsing disease. However, this chimeric anti-CD20 monoclonal antibody often leads to lower IgG levels. This adverse effect significantly increases the risk of severe infections in children.
The meta-analysis evaluated 33 eligible publications involving children with nephrotic syndrome. Findings revealed a pooled incidence of 11.4% for hypogammaglobulinemia. Notably, patients receiving rituximab faced an 81% higher risk compared to those not receiving the drug. This equates to approximately 68 additional cases per 1,000 patients.
Low immunoglobulin levels correlate with increased infection rates. Specifically, 18% of the 517 hypogammaglobulinemia episodes involved infections. Although most were manageable, four infections unfortunately proved fatal. Therefore, clinicians must carefully weigh these risks against the therapeutic benefits of rituximab for nephrotic syndrome management.
Current evidence suggests that regular IgG monitoring is essential for pediatric patients. Experts recommend checking levels before, during, and after therapy. Furthermore, assessing pre-treatment IgG levels helps identify children at higher risk for persistent deficiency. Consequently, proactive management and vigilance can prevent life-threatening complications in this vulnerable population.
The pooled incidence of hypogammaglobulinemia is 11.4% in children with nephrotic syndrome who receive rituximab treatment.
Rituximab increases the risk by 1.81 times, which is equivalent to about 68 additional cases of hypogammaglobulinemia per 1,000 patients.
Yes, while many are manageable, about 18% of patients with hypogammaglobulinemia experience infections, and some cases can be fatal.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Chung J et al. Rituximab-induced hypogammaglobulinemia in childhood nephrotic syndrome: a systematic review and meta-analysis. Eur J Pediatr. 2026 Mar 17. doi: undefined. PMID: 41843217.
Shatat IF et al. Rituximab-induced persistent hypogammaglobulinemia in children with nephrotic syndrome: common or rare? Nephrol Dial Transplant. 2025;40(10):1815-1819.
Chan EY et al. Rituximab-induced hypogammaglobulinemia in nephrotic syndrome: what is the true burden? Pediatr Nephrol. 2024 Oct;39(10):3129.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A meta-analysis finds an 11.4% incidence of hypogammaglobulinemia in children treated with rituximab for nephrotic syndrome, increasing infection risks....
5 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
